Benjamin Movsas1, Daniel Hunt2, Deborah Watkins-Bruner3, W Robert Lee4, Heather Tharpe5, Desiree Goldstein6, Joan Moore7, Ian S Dayes8, Sara Parise9, Howard Sandler10. 1. Henry Ford Health System, Detroit, Michigan. Electronic address: bmovsas1@hfhs.org. 2. RTOG Statistical Center, Philadelphia, Pennsylvania. 3. Emory University School of Nursing, Atlanta, Georgia. 4. Duke University School of Medicine, Durham, North Carolina. 5. Summa Health System Hospital, Akron, Ohio. 6. Kaiser Permanente Santa Clara Medical Center, Santa Clara, California. 7. York Cancer Center, Hanover, Pennsylvania. 8. McMaster University, Juravinski Cancer Center Hamilton Health Sciences, Hamilton, Ontario, Canada. 9. North Shore-Long Island Jewish Health System, Monter Cancer Center, Lake Success, New York. 10. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
PURPOSE: Missing data are a significant problem in clinical trials, particularly for quality of life (QOL), which cannot be obtained retrospectively. The purpose of this study was to evaluate the feasibility of an electronic web-based strategy for QOL data collection in a cooperative group radiation oncology trial setting. METHODS AND MATERIALS: Radiation Therapy Oncology Group (RTOG) 0828 was a prospective National Cancer Institute cooperative group companion study of RTOG-0415, a randomized study of conventional versus hypofractionated radiation. Forty-nine English-speaking patients with favorable risk prostate cancer who enrolled on RTOG-0415 consented to using web-based technology for completing QOL. In RTOG-0415, using paper forms, the 6-month QOL compliance rate was 52%. The purpose of RTOG-0828 was to test the feasibility of a web-based strategy with the goal of increasing the 6-month QOL completion rate by 25% (from 52% to 77%) for a relative improvement of ~50%. The web-based tool used in this study was VisionTree Optimal Care (VTOC; VisionTree Software, Inc, San Diego, CA), a Health-Insurance-Portability-Accountability-Act secure, online technology that allows real-time tracking and e-mail reminders. The primary endpoint was the 6-month compliance rate for the validated QOL instrument, Expanded Prostate Index Composite. RESULTS: The QOL completion rate at baseline was 98%. Compared with the prior 52% QOL completion rate at 6 months using paper forms, the QOL web-based completion rate at 6 months was 90% (2-sided P value < .001). At 12 months, the EPIC completion rate was 82% (compared with 36% using paper forms). CONCLUSIONS: This RTOG study suggests that a web-based strategy to collect QOL appears to be feasible in the cooperative group radiation oncology trial setting and is associated with an increase in the 6-month QOL compliance rate compared with the prior method of using paper forms. The RTOG plans to further test this strategy in a head-and-neck cancer trial across all participating RTOG sites.
RCT Entities:
PURPOSE: Missing data are a significant problem in clinical trials, particularly for quality of life (QOL), which cannot be obtained retrospectively. The purpose of this study was to evaluate the feasibility of an electronic web-based strategy for QOL data collection in a cooperative group radiation oncology trial setting. METHODS AND MATERIALS: Radiation Therapy Oncology Group (RTOG) 0828 was a prospective National Cancer Institute cooperative group companion study of RTOG-0415, a randomized study of conventional versus hypofractionated radiation. Forty-nine English-speaking patients with favorable risk prostate cancer who enrolled on RTOG-0415 consented to using web-based technology for completing QOL. In RTOG-0415, using paper forms, the 6-month QOL compliance rate was 52%. The purpose of RTOG-0828 was to test the feasibility of a web-based strategy with the goal of increasing the 6-month QOL completion rate by 25% (from 52% to 77%) for a relative improvement of ~50%. The web-based tool used in this study was VisionTree Optimal Care (VTOC; VisionTree Software, Inc, San Diego, CA), a Health-Insurance-Portability-Accountability-Act secure, online technology that allows real-time tracking and e-mail reminders. The primary endpoint was the 6-month compliance rate for the validated QOL instrument, Expanded Prostate Index Composite. RESULTS: The QOL completion rate at baseline was 98%. Compared with the prior 52% QOL completion rate at 6 months using paper forms, the QOL web-based completion rate at 6 months was 90% (2-sided P value < .001). At 12 months, the EPIC completion rate was 82% (compared with 36% using paper forms). CONCLUSIONS: This RTOG study suggests that a web-based strategy to collect QOL appears to be feasible in the cooperative group radiation oncology trial setting and is associated with an increase in the 6-month QOL compliance rate compared with the prior method of using paper forms. The RTOG plans to further test this strategy in a head-and-neck cancer trial across all participating RTOG sites.
Authors: David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays Journal: J Clin Epidemiol Date: 2010-08-04 Impact factor: 6.437
Authors: Johannes Giesinger; Georg Kemmler; Verena Meraner; Eva-Maria Gamper; Anne Oberguggenberger; Barbara Sperner-Unterweger; Bernhard Holzner Journal: Breast Care (Basel) Date: 2009-06-26 Impact factor: 2.860
Authors: Astrid Erharter; Johannes Giesinger; Georg Kemmler; Gabriele Schauer-Maurer; Guenter Stockhammer; Armin Muigg; Markus Hutterer; Gerhard Rumpold; Barbara Sperner-Unterweger; Bernhard Holzner Journal: J Pain Symptom Manage Date: 2010-02 Impact factor: 3.612
Authors: Stephanie L Pugh; Joseph P Rodgers; Katherine A Yeager; Ronald C Chen; Benjamin Movsas; Roseann Bonanni; James Dignam; Deborah W Bruner Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-24 Impact factor: 7.038
Authors: Jeffrey M Vainshtein; Dominic H Moon; Felix Y Feng; Douglas B Chepeha; Avraham Eisbruch; Matthew H Stenmark Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-01 Impact factor: 7.038
Authors: Pamela J Atherton; Deborah W Watkins-Bruner; Carolyn Gotay; Carol M Moinpour; Daniel V Satele; Kathryn A Winter; Paul L Schaefer; Benjamin Movsas; Jeff A Sloan Journal: J Pain Symptom Manage Date: 2015-05-30 Impact factor: 3.612
Authors: Benjamin Movsas; Chen Hu; Jeffrey Sloan; Jeffrey Bradley; Ritsuko Komaki; Gregory Masters; Vivek Kavadi; Samir Narayan; Jeff Michalski; Douglas W Johnson; Christopher Koprowski; Walter J Curran; Yolanda I Garces; Rakesh Gaur; Raymond B Wynn; John Schallenkamp; Daphna Y Gelblum; Robert M MacRae; Rebecca Paulus; Hak Choy Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777
Authors: Jennifer Ai-Lian Woo; Leonard N Chen; Hongkun Wang; Robyn A Cyr; Onita Bhattasali; Joy S Kim; Rudy Moures; Thomas M Yung; Siyuan Lei; Brian Timothy Collins; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins Journal: Front Oncol Date: 2015-03-31 Impact factor: 6.244
Authors: Charles A Kunos; Jacek Capala; Adam P Dicker; Benjamin Movsas; Susan Percy Ivy; Lori M Minasian Journal: Front Oncol Date: 2019-10-10 Impact factor: 6.244
Authors: Patricia Holch; Simon Pini; Ann M Henry; Susan Davidson; Jacki Routledge; Julia Brown; Kate Absolom; Alexandra Gilbert; Kevin Franks; Claire Hulme; Carolyn Morris; Galina Velikova Journal: Pilot Feasibility Stud Date: 2018-06-05